Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GCK | P35557 | 11/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176835 | 0.90 | GCK (0.55) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2664728 | 0.90 | GCK (0.60) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2176809 | 0.87 | RAB9A (0.56) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2176268 | 0.85 | GCK (0.70) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2176262 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2664748 | 0.84 | GCK (0.64) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| Bromide SCHEMBL2175824 | 0.82 | GCK (0.50) | SMN1; SMN2MAPTGCKRAB9ANPC1 | |
| SCHEMBL1492953 | 0.78 | RAB9A (0.53) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2664578 | 0.78 | GCK (0.61) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2176452 | 0.78 | NPC1 (0.54) | SMN1; SMN2GCKRAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | GCK, GCKR, HK1 | SMN1; SMN2 4303/4885BRD4 2256/4885MAPT 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.